<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03813056</url>
  </required_header>
  <id_info>
    <org_study_id>RDMEK-01</org_study_id>
    <nct_id>NCT03813056</nct_id>
  </id_info>
  <brief_title>Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' Dystrophy</brief_title>
  <official_title>A Phase II, Interventional, Double-blind, Single-center Study of the Effects of Ripasudil on Cornea Clearing After Descemet Membrane Endothelial Keratoplasty in Subjects With Fuchs' Endothelial Corneal Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael D. Straiko, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lions VisionGift Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eye Bank Association of America</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Legacy Health System</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, published literature has reported that performing a descemetorhexis in combination
      with topical Rho kinase (ROCK) inhibitor therapy was successful in clearing edematous corneas
      in patients with Fuchs Endothelial Corneal Dystrophy.

      Ripasudil hydrochloride hydrate( Glanatec ophthalmic solution 0.4%), a potent ROCK inhibitor,
      has been approved in Japan since 2014 for ocular use in the treatment of glaucoma. Ripasudil
      acts as an IOP-lowering drug by affecting aqueous outflow through the trabecular meshwork and
      Schlemm's canal.

      The goal of this study is to test the potential benefits of Ripasudil therapy administered
      after Descemet Membrane Endothelial Keratoplasty (DMEK) surgery. We believe that performing a
      standard DMEK surgery in combination with Ripasudil treatment in patients with Fuchs
      Endothelial Corneal Dystrophy could accelerate endothelial cell healing and clear edematous
      corneas faster, with less post-operative complications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to corneal clearance</measure>
    <time_frame>6 months</time_frame>
    <description>Slit lamp examinations and corneal OCT measurements will be taken in a longitudinal fashion to compare corneal clearance and stabilization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>6 months</time_frame>
    <description>Longitudinal best corrected visual acuity tests will be performed to compare the time course of best vision attained and reported in Snellen units.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial cell density</measure>
    <time_frame>6 months</time_frame>
    <description>Specular imaging will be conducted at 3 and 6 month postoperative to compare endothelial cells loss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post surgery complications</measure>
    <time_frame>6 months</time_frame>
    <description>Number of graft detachments requiring a re-bubble procedure and number of graft failures will be recorded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Fuchs Endothelial Dystrophy</condition>
  <arm_group>
    <arm_group_label>Glanatec</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glanatec eye drops will be administered 6x per day for 2-4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Optive artificial tears will be administered 6x per day for 2-4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glanatec</intervention_name>
    <description>Rho kinase Inhibitor</description>
    <arm_group_label>Glanatec</arm_group_label>
    <other_name>Ripasudil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Optive, Ophthalmic Solution</intervention_name>
    <description>artificial tears (placebo)</description>
    <arm_group_label>Placebo Control</arm_group_label>
    <other_name>Optive, artificial tears</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Descemet Membrane Endothelial Keratoplasty</intervention_name>
    <description>Partial thickness corneal transplant that replaces only the diseased corneal endothelium and descemet membrane of the recipient.</description>
    <arm_group_label>Glanatec</arm_group_label>
    <arm_group_label>Placebo Control</arm_group_label>
    <other_name>DMEK</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed clinically with Fuchs endothelial corneal dystrophy by the study
             investigator.

          -  Phakic or pseudophakic with posterior capsule supported, suture-fixated, or
             sulcus-supported posterior chamber intraocular lens.

          -  Fuchs dystrophy grades 2-5 on the Krachmer grading scale.

          -  Presence of central guttae and/or stromal edema being the primary cause of decreased
             vision.

          -  The peripheral cornea to the central 6mm is devoid of guttata changes.

          -  Best corrected visual acuity in the study eye is 20/40 or worse with glare testing at
             study enrollment.

        Exclusion Criteria:

          -  Uncontrolled glaucoma (IOP &gt;25 mmHg).

          -  Presence of secondary corneal pathology such as infective or autoimmune keratitis.

          -  Advanced corneal stromal edema with bullae on slit-lamp biomicroscopy.

          -  History of herpes simplex virus or cytomegalovirus keratitis.

          -  Prior penetrating keratoplasty.

          -  Aphakic in study eye.

          -  Allergy to any component of the Ripasudil hydrochloride hydrate 0.4% that will be used
             in the course of the study.

          -  Tubes or trabeculectomy from prior glaucoma surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael D Straiko, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Devers Eye Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alex J Bauer, B.S.</last_name>
    <phone>503-413-8377</phone>
    <email>alex@visiongift.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael D Straiko, M.D.</last_name>
    <phone>503-413-8032</phone>
    <email>mike.straiko@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Devers Eye Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex J Bauer, B.S.</last_name>
      <phone>503-413-8377</phone>
      <email>alex@visiongift.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>January 19, 2019</study_first_submitted>
  <study_first_submitted_qc>January 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2019</study_first_posted>
  <last_update_submitted>August 17, 2019</last_update_submitted>
  <last_update_submitted_qc>August 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Legacy Health System</investigator_affiliation>
    <investigator_full_name>Michael D. Straiko, MD</investigator_full_name>
    <investigator_title>Associate Director of Corneal Services, Devers Eye Institute</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fuchs' Endothelial Dystrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

